Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Cash: 2010-2025

Historic Change in Cash for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $37.1 million.

  • Catalyst Pharmaceuticals' Change in Cash fell 44.34% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.6 million, marking a year-over-year decrease of 22.96%. This contributed to the annual value of $379.9 million for FY2024, which is 336.33% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Change in Cash is $37.1 million, which was down 48.59% from $72.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Cash ranged from a high of $172.8 million in Q1 2024 and a low of -$150.1 million during Q1 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Change in Cash value was $63.1 million (recorded in 2025), while the average stood at $35.6 million.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 851.36% in 2021, then tumbled by 2,267.58% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Change in Cash (Quarterly) stood at $16.6 million in 2021, then surged by 154.86% to $42.3 million in 2022, then plummeted by 60.63% to $16.7 million in 2023, then spiked by 351.38% to $75.2 million in 2024, then crashed by 44.34% to $37.1 million in 2025.
  • Its Change in Cash was $37.1 million in Q3 2025, compared to $72.1 million in Q2 2025 and $63.1 million in Q1 2025.